Skip to main content
    C

    CG Oncology, Inc. Common stock (CGON)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $84.78
    +10.38 (+13.95%)

    Market Cap: $6.65B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    CG Oncology, Inc. Common stock (CGON) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect CG Oncology, Inc. Common stock (CGON) to earn -$2.96 per share in the fiscal year ending Dec 31, 2026, on revenue of $4.54M. Of 15 analysts, 14 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 10 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 15 ratings average 1.80, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 93% of the ratings.

    RatingAnalystsShare
    Strong Buy426.7%
    Buy1066.7%
    Hold16.7%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    15

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 2095.6%.

    Fiscal year ending Dec 31, 2026
    -$2.96
    EPS consensus, revenue $4.54M
    Fiscal year ending Dec 31, 2027
    -$2.78
    EPS consensus, revenue $99.68M
    Next report
    Feb 25, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$2.96-$3.14 to -$2.4111$4.54M$3.80M to $6.06M12
    Dec 31, 2027-$2.78-$4.38 to -$1.8512$99.68MN/A11

    Quarterly Estimates

    The EPS consensus rises from -$0.84 for the quarter ending Dec 31, 2026 to -$0.74 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.84-$1.01 to -$0.6216$644303N/A14
    Mar 31, 2027-$0.74-$0.80 to -$0.663$400000N/A4

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 3 upward and 17 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 2026010
    Fiscal year ending Dec 31, 202727
    Quarter ending Mar 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$3.22.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$2.96-$3.23-$3.23-$3.20-$3.22N/A
    Fiscal year ending Dec 31, 2027-$2.78-$3.02-$3.02-$3.02-$2.90N/A
    Quarter ending Mar 31, 2027-$0.74-$0.89-$0.89-$0.89-$0.89N/A

    Frequently Asked Questions About CGON

    What is the CGON stock forecast?

    Consensus analyst estimates put CG Oncology, Inc. Common stock's EPS at -$2.96 for the fiscal year ending Dec 31, 2026, on revenue of $4.54M. The consensus rating from 15 analysts is Buy.

    How do analysts rate CGON stock?

    Of 15 analysts covering CG Oncology, Inc. Common stock, 4 rate it Strong Buy, 10 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from CGON next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.96, with estimates from -$3.14 to -$2.41 from 11 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.78, with estimates from -$4.38 to -$1.85 from 12 analysts.

    What revenue do analysts expect from CG Oncology, Inc. Common stock next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $4.54M, with estimates from $3.80M to $6.06M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $99.68M.

    How many analysts cover CGON?

    15 analysts rate CG Oncology, Inc. Common stock stock, and 11 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.